Proactive management of adverse events maintains the clinical benefit of ixabepilone

Oncologist

Volumn 14, Issue 5, 2009, Pages 448-455

  Yardley, Denise A ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Breast cancer; Epothilones; Ixabepilone; Safety; Tolerability; Treatment

Indexed keywords

AMPRENAVIR; ANTHRACYCLINE; ATAZANAVIR; CAPECITABINE; CLARITHROMYCIN; CORTICOSTEROID; CREMOPHOR; DELAVIRDINE; DIPHENHYDRAMINE; EMOLLIENT AGENT; GABAPENTIN; GRANISETRON; INDINAVIR; ITRACONAZOLE; IXABEPILONE; KETOCONAZOLE; LOPERAMIDE; METOCLOPRAMIDE; MODAFINIL; NELFINAVIR; ONDANSETRON; PREGABALIN; PROCHLORPERAZINE; PYRIDOXINE; RANITIDINE; RITONAVIR; SAQUINAVIR; TELITHROMYCIN; VITAMIN B COMPLEX; VORICONAZOLE;

ABDOMINAL PAIN; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANALGESIA; ANEMIA; ANOREXIA; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONVALESCENCE; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FLUSHING; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE FAILURE; HUMAN; HYPERSENSITIVITY REACTION; LEUKOPENIA; LIVER DISEASE; MAXIMUM TOLERATED DOSE; MICROTUBULE; MONOTHERAPY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; NEUTROPHIL COUNT; PARESTHESIA; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PREMEDICATION; PRIORITY JOURNAL; PROPHYLAXIS; RASH; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THERAPY DELAY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 CYP3A; EPOTHILONES; FEMALE; HUMANS; LIVER; PERIPHERAL NERVOUS SYSTEM DISEASES; TUBULIN MODULATORS;

EID: 66349122712     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0284     Document Type: Review

References (28)

1. Vahdat L. Ixabepilone: A novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. The Oncologist 2008;13:214-221.
2. Goodin S, Kane MP, Rubin EH. Epothilones: Mechanism of action and biologic activity. J Clin Oncol 2004;22:2015-2025.
3. Bode CJ, Gupta ML Jr., Reiff EA et al. Epothilone and paclitaxel: Unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 2002;41:3870-3874. (Pubitemid 34251025)
4. Lee FYF, Borzilleri R, Fairchild CR et al. BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;7:1429-1437. (Pubitemid 32708699)
5. Lee FYF, Smykla R, Johnston K et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 2009;63:201-212.
6. Lee JJ, Swain SM. Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Semin Oncol 2005;32(suppl 7):S22-S26. (Pubitemid 41785443)
7. Kuo MT. Roles of multidrug resistance genes in breast cancer chemoresistance. Adv Exp Med Biol 2007;608:23-30.
8. Perez EA, Lerzo G, Pivot X et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407-3414. (Pubitemid 47310876)
9. Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 2007;25:5210-5217. (Pubitemid 350232252)
10. Thomas E, Tabernero J, Fornier M et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25:3399-3406. (Pubitemid 47310875)
11. Low JA, Wedam SB, Lee JJ et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005;23:2726-2734. (Pubitemid 46179462)
12. Roché H, Yelle L, Cognetti F et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25:3415-3420. (Pubitemid 47310877)
13. Denduluri N, Low JA, Lee JJ et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007;25:3421-3427. (Pubitemid 47310878)
14. Baselga J, Gianni L, Llombart A et al. Predicting response to ixabepilone: Genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer (BC). Breast Cancer Res Treat 2005;94(suppl 1):S31.
15. Lee FYF, Camuso A, Castenada C et al. Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts. J Clin Oncol 2006;24:597s.
16. Hortobagyi GN, Perez E, Vrdoljak E et al. Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: Results from two randomized phase III trials. ASCO 2008 Breast Cancer Symposium Proceedings, Abstract 186.
17. Ixempra™ Kit (ixabepilone) for injection [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, October 2007.
18. Aghajanian C, O'Connor OA, Cohen M, et al. Final results from a phase I trial of ixabepilone given every three weeks in patients with advanced malignancies and lymphoma. J Clin Oncol 2006;24(18 suppl):88s.
19. Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-3205. (Pubitemid 46638957)
20. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol 2006;24:1633-1642. (Pubitemid 46638788)
21. Head KA. Peripheral neuropathy: Pathogenic mechanisms and alternative therapies. Altern Med Rev 2006;11:294-329. (Pubitemid 46037130)
22. Ludwig H, Zojer N. Supportive care. Ann Oncol 2007;18(suppl 1):i37-i44. (Pubitemid 46344639)
23. Smith GF, Toonen TR. Primary care of the patient with cancer. Am Fam Physician 2007;75:1207-1214. (Pubitemid 46631818)
24. Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs 2004;8(suppl 1):S31-S40. (Pubitemid 39194085)
25. Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 2006;12:131-141. (Pubitemid 44696441)
26. Goel S, Cohen M, Cömezoglu SN et al. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: A first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res 2008;14:2701-2709.
27. Robertson P Jr, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003;42:123-137. (Pubitemid 36188553)
28. Verstappen CC, Helmans JJ, Hoekman K et al. Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs 2003;63:1549-1563. (Pubitemid 36976138)